EGFR and lung cancer: To investigate whether MA also increased the sensitivity of HCC827OR cells to osimertinib, a CCK-8 assay showed that HCC827OR cells were also more resistant to MA than the parental HCC827 cells (Figure 6G), but the combination of MA and osimertinib significantly inhibited the viability of HCC827 (Figure 6H) and HCC827OR (Figure 6I) cells, suggesting that MA overcame acquired resistance to EGFR-TKIs in lung cancer cells.